PHIO PHARMACEUTICALS CORP. Total Liabilities and Equity
PHIO PHARMACEUTICALS CORP. (PHIO) had Total Liabilities and Equity of $14.31 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-06
- 2026-06-30: Liabilities and Equity $14.31M.
- 2026-03-31: Liabilities and Equity $17.41M.
- 2025-12-31: Liabilities and Equity $21.49M.
- 2025-09-30: Liabilities and Equity $11.51M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $14.31M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $17.41M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $21.49M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $11.51M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $11.30M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $13.44M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $5.74M 10-K · filed 2026-03-05 |
| 2024-09-30 | $5.87M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $5.30M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $6.85M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $9.36M 10-K · filed 2025-03-31 |
| 2023-09-30 | $9.54M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $12.30M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $9.71M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $12.81M 10-K · filed 2024-04-01 |
| 2022-09-30 | $15.79M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $20.14M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $22.16M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $25.17M 10-K · filed 2023-03-22 |
| 2021-09-30 | $27.94M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $31.66M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $33.86M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $15.74M 10-K · filed 2022-03-22 |
| 2020-09-30 | $18.24M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $20.21M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $14.30M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $8.04M 10-K · filed 2021-03-25 |
| 2019-09-30 | $10.08M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $12.11M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $13.68M 10-Q · filed 2019-05-14 |
| 2018-12-31 | $15.32M 10-K · filed 2020-03-26 |
| 2018-09-30 | $3.81M 10-Q · filed 2018-11-14 |
| 2018-06-30 | $6.03M 10-Q · filed 2018-08-14 |
| 2018-03-31 | $3.09M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $4.10M 10-K · filed 2019-03-27 |
| 2017-09-30 | $6.03M 10-Q/A · filed 2018-03-26 |
| 2017-06-30 | $8.39M 10-Q/A · filed 2018-03-26 |
| 2017-03-31 | $10.51M 10-Q/A · filed 2018-03-26 |
| 2016-12-31 | $13.40M 10-Q/A · filed 2018-03-26 |
| 2016-09-30 | $4.90M 10-Q · filed 2016-11-10 |
| 2016-06-30 | $6.52M 10-Q · filed 2016-08-11 |
| 2016-03-31 | $8.17M 10-Q · filed 2016-05-12 |
| 2015-12-31 | $11.16M 10-K · filed 2017-03-30 |
| 2015-09-30 | $12.70M 10-Q · filed 2015-11-12 |
| 2015-06-30 | $14.95M 10-Q · filed 2015-08-12 |
| 2015-03-31 | $7.17M 10-Q · filed 2015-05-13 |
| 2014-12-31 | $9.19M 10-K · filed 2016-03-30 |
| 2014-09-30 | $10.90M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $12.55M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $12.46M 10-Q · filed 2014-05-14 |
| 2013-12-31 | $14.94M 10-K · filed 2015-03-30 |
| 2013-09-30 | $16.21M 10-Q · filed 2013-11-14 |
| 2013-06-30 | $18.00M 10-Q · filed 2013-08-14 |
| 2013-03-31 | $19.97M 10-Q · filed 2013-05-15 |
| 2012-12-31 | $5.59M 10-K · filed 2014-03-28 |
| 2012-09-30 | $6.71M 10-Q · filed 2012-11-13 |
| 2012-06-30 | $8.02M 10-Q · filed 2012-08-14 |
| 2012-03-31 | $1.33M 10-Q · filed 2012-05-14 |
| 2011-12-31 | $1.69M 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |